Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Debt (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Total Debt data on record, last reported at $609.5 million in Q3 2025.

  • For Q3 2025, Total Debt rose 2.15% year-over-year to $609.5 million; the TTM value through Sep 2025 reached $609.5 million, up 2.15%, while the annual FY2024 figure was $601.9 million, 2.01% up from the prior year.
  • Total Debt reached $609.5 million in Q3 2025 per AMPH's latest filing, roughly flat from $608.7 million in the prior quarter.
  • Across five years, Total Debt topped out at $638.6 million in Q3 2023 and bottomed at $38.5 million in Q2 2021.
  • Average Total Debt over 5 years is $344.7 million, with a median of $501.2 million recorded in 2023.
  • Peak YoY movement for Total Debt: decreased 7.02% in 2021, then soared 743.74% in 2023.
  • A 5-year view of Total Debt shows it stood at $77.0 million in 2021, then fell by 1.42% to $75.9 million in 2022, then skyrocketed by 677.51% to $590.0 million in 2023, then rose by 2.01% to $601.9 million in 2024, then increased by 1.27% to $609.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $609.5 million in Q3 2025, $608.7 million in Q2 2025, and $604.1 million in Q1 2025.